Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavyret for HCV prevention in kidney transplant recipients
NCT04515797Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- May 2021
- Primary completion
- Aug 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of glecaprevir in hepatitis C (HCV), sponsored by Massachusetts General Hospital. Started May 2021; status: terminated.
02
Drugs
glecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04515797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515797.